The secondary endpoints will be able to suss out t

The secondary endpoints will be able to suss out those nuances. For example, you have Patient A on leronlimab who makes a full recovery on day 3. Then you have Patient B on SOC who survives after 28 days but continues to linger on life support. If looking at all cause mortality @ day 28 and the pure statistic, one would have to conclude that leronlimab was ineffective. Obviously, in this example leronlimab is extremely effective. That's why expectations for quick & immediate readout of mortality statistics would be unwise. You really should look at the other data before PR'ing anything.